129 related articles for article (PubMed ID: 38466231)
1. Uncovering PROTAC Sensitivity and Efficacy by Multidimensional Proteome Profiling: A Case for STAT3.
Suo Y; Du D; Chen C; Zhu H; Wang X; Song N; Lu D; Yang Y; Li J; Wang J; Luo Z; Zhou B; Luo C; Zhou H
J Med Chem; 2024 Mar; 67(6):4804-4818. PubMed ID: 38466231
[TBL] [Abstract][Full Text] [Related]
2. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
4. Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
Hall J; Zhang Z; Bhattacharya S; Wang D; Alcantara M; Liang Y; Swiderski P; Forman S; Kwak L; Vaidehi N; Kortylewski M
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102137. PubMed ID: 38384444
[TBL] [Abstract][Full Text] [Related]
5. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.
Bai L; Zhou H; Xu R; Zhao Y; Chinnaswamy K; McEachern D; Chen J; Yang CY; Liu Z; Wang M; Liu L; Jiang H; Wen B; Kumar P; Meagher JL; Sun D; Stuckey JA; Wang S
Cancer Cell; 2019 Nov; 36(5):498-511.e17. PubMed ID: 31715132
[TBL] [Abstract][Full Text] [Related]
6. Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
Hall J; Zhang Z; Wang D; Bhattacharya S; Alcantara M; Liang Y; Swiderski P; Forman S; Kwak L; Vaidehi N; Kortylewski M
bioRxiv; 2023 Aug; ():. PubMed ID: 37577590
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer.
Jin J; Wu Y; Zhao Z; Wu Y; Zhou YD; Liu S; Sun Q; Yang G; Lin J; Nagle DG; Qin J; Zhang Z; Chen HZ; Zhang W; Sun S; Luan X
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509291
[TBL] [Abstract][Full Text] [Related]
8. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
9. Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3?
Heppler LN; Frank DA
Cancer Cell; 2019 Nov; 36(5):459-461. PubMed ID: 31715126
[TBL] [Abstract][Full Text] [Related]
10. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
Hu M; Zhou W; Wang Y; Yao D; Ye T; Yao Y; Chen B; Liu G; Yang X; Wang W; Xie Y
Acta Pharm Sin B; 2020 Oct; 10(10):1943-1953. PubMed ID: 33163345
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
12. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
Hanafi M; Chen X; Neamati N
J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology.
Mukhamejanova Z; Tong Y; Xiang Q; Xu F; Pang J
Curr Med Chem; 2021; 28(7):1304-1327. PubMed ID: 32164504
[TBL] [Abstract][Full Text] [Related]
15. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
16. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
18. Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells.
Wang X; Zhao Y; Li X; Zhang Q; He J; Liu Y; Li M; Luo Z
Nano Lett; 2024 Apr; ():. PubMed ID: 38598369
[TBL] [Abstract][Full Text] [Related]
19. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
20. A GPX4 non-enzymatic domain and MDM2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.
Niu F; Yang R; Feng H; Liu Y; Liu R; Ma B
Biochem Biophys Res Commun; 2023 Dec; 684():149125. PubMed ID: 37897912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
